The First Clinical Medical College of Shandong University of Traditional Chinese Medicine, Jinan City, Shandong Province, China.
Teacher Development Center of Shandong University of Traditional Chinese Medicine, Jinan City, Shandong Province, China.
Medicine (Baltimore). 2021 Nov 19;100(46):e27501. doi: 10.1097/MD.0000000000027501.
: As a compound preparation of traditional Chinese and western medicine included in Volume 20 of Chinese traditional Medicine prescription, Zhenju antihypertensive tablet has been widely used in the treatment of patients with essential hypertension (EH) for many years. This study intends to evaluate the efficacy, safety and vascular endothelial function of Zhenju antihypertensive tablet in the treatment of essential hypertension.
: The search strategies of different websites were searched on Cochrane Central controlled Trials Registry, PubMed, excerpt database, Chinese Biomedical Literature Database, China National knowledge Infrastructure, Chinese Science and Technology Journal Database, WanFang, and other websites. All qualified studies were confirmed to include randomized controlled trials. The search time range was from January 1, 1900 to August 31, 2021. At the same time, the list of references and related reviews were checked. Two evaluators were responsible for the extraction and management of the data independently. The literature quality was evaluated according to Cochrane manual 4.2.2. Heterogeneity test and Meta analysis were carried out by Review ManagerV.5.3 software. The bias risk included in the study was evaluated by Cochrane "bias risk" tool. In addition, the relevant statistical data were evaluated by GRADE3.6 evidence quality grading system.
: This study intends evaluate the efficacy and safety of Zhenju antihypertensive tablet in the treatment of EH from 4 aspects, including changes in blood pressure (systolic blood pressure, diastolic Blood pressure), effective hypotension, changes in endothelial function (NO, the level of plasma endothelin-1 in serum), and adverse reactions.
: The conclusion of this study intends to provide evidence for judging the effectiveness and safety of ZJAHC intervention on EH patients and their endothelial function.PROSPERO registration number: PROSPERO CRD42021235309.
珍菊降压片是由中药和西药组成的复方制剂，收载于《中药成方制剂》第 20 册，多年来广泛用于原发性高血压（EH）患者的治疗。本研究旨在评价珍菊降压片治疗 EH 的疗效、安全性及血管内皮功能。
在 Cochrane 对照试验中心注册库、PubMed、摘录数据库、中国生物医学文献数据库、中国知网、中国科技期刊数据库、万方等网站检索不同网站的检索策略。所有合格的研究均被确认为包括随机对照试验。搜索时间范围为 1900 年 1 月 1 日至 2021 年 8 月 31 日。同时，检查参考文献和相关综述。两名评估员负责独立提取和管理数据。根据 Cochrane 手册 4.2.2 评价文献质量。采用 Review ManagerV.5.3 软件进行异质性检验和 Meta 分析。通过 Cochrane“偏倚风险”工具评估研究中包含的偏倚风险。此外，使用 GRADE3.6 证据质量分级系统评估相关统计数据。
本研究从血压（收缩压、舒张压）变化、有效降压、内皮功能变化（NO、血清中血浆内皮素-1 水平）和不良反应 4 个方面评价珍菊降压片治疗 EH 的疗效和安全性。
本研究的结论旨在为判断 ZJAHC 干预对 EH 患者及其内皮功能的有效性和安全性提供证据。PROSPERO 注册号：PROSPERO CRD42021235309。
